 <p>JOHNS HOPKINS MEDICINE JOHNS HOPKINS HEALTHCARE</p>	Johns Hopkins HealthCare LLC	<i>Policy Number</i>	MEDS105
	Pharmacy Public Pharmacy Management Drug Policies	<i>Effective Date</i>	07/01/2017
		<i>Review Date</i>	10/19/2022
	<i>Subject</i>	<i>Revision Date</i>	07/28/2022
	PPMCO Short-Acting & Long-Acting Opioids	<i>Page</i>	1 of 5

This document applies to the following Participating Organizations:

Priority Partners

Keywords: opioids


Table of Contents	Page Number
I. POLICY	1
II. POLICY CRITERIA	1
A. Non-Formulary Opioids	1
B. Formulary Short-acting Opioids at quantities that exceed 90 daily MME	3
C. Formulary Long-acting Opioids	3
D. Formulary Short-acting Opioids at quantities greater than Plan's Quantity Limits	3
E. Request for use of greater than a 7-day supply of formulary short-acting opioids	4
III. OPIOID QUANTITY LIMITS	4
IV. AUTHORIZATION PERIOD/LIMITATIONS	4
V. EXCLUSIONS	4
VI. REFERENCES	4
VII. APPROVALS	5

I. POLICY


1. Short-acting & Long-Acting narcotic analgesics (opioids) may be subject to prior authorization and/or quantity limits to ensure safe dosing and appropriate use consistent with FDA and CDC recommendations. These products require prior authorization for doses greater than the established quantity limit. The process for initiating a prior authorization request can be found in policy PHARM 20.
2. PPMCO members are subject to the Priority Partners formulary, available at www.ppmco.org.

II. POLICY CRITERIA

- A. Requests for **Non-Formulary Opioids**:
 1. **Non-formulary short-acting opioids** may be approved when ALL the following criteria are met:
 - a. Documentation has been submitted showing the following:
 - I. Diagnosis of breakthrough pain while the patient is opioid tolerant, and receiving opioid therapy for underlying persistent cancer pain
 - II. Patient is utilizing an adequate dosing of a long-acting (maintenance, around-the-clock) opioid
 - III. Patient is able to comply with child-safe storage and disposal requirements
 - IV. Patient has evidence of medical necessity supported by ONE of the following:
 - i. Therapeutic failure of two or more adequately dosed short-acting formulary opioids within the previous 180 days per pharmacy claims
 - ii. Allergy to one formulary drug
 - iii. Successful drug maintenance on the requested medication when changing to an alternative drug may produce a potential health risk
 - V. Prescriber has attested to ALL the following:

 <p>JOHNS HOPKINS MEDICINE JOHNS HOPKINS HEALTHCARE</p>	Johns Hopkins HealthCare LLC Pharmacy Public Pharmacy Management Drug Policies	<i>Policy Number</i>	MEDS105	
		<i>Effective Date</i>	07/01/2017	
		<i>Review Date</i>	10/19/2022	
	<i>Subject</i>	PPMCO Short-Acting & Long-Acting Opioids	<i>Revision Date</i>	07/28/2022
			<i>Page</i>	2 of 5

- i. Prescriber has reviewed controlled substance prescriptions in the Prescription Drug Monitoring Program through CRISP (Chesapeake Regional Information System) for prescriptions from other providers
 - ii. Naloxone prescription has been provided or offered to patient/patient's household.
 - iii. Patient will have random urine drug screen
 - A. **Caveat: Urine drug screening is not applicable for patients being discharged from inpatient facility and transitioning to outpatient care*
 - iv. A Patient-Prescriber Pain Management/Opioid Treatment Agreement/Contract has been signed, and placed in the patient's medical record
 - A. **Caveats: Patient-Prescriber is not applicable for patients being discharged from inpatient facility and transitioning to outpatient care. However, provider must attest to ALL of the following:*
 1. *The risks and benefits associated with opioid use have been discussed with the patient/patient's household*
 2. *One of the following:*
 - a. *The prescribed treatment will be for less than 30 days*
 - b. *The need for further opioid use will be re-evaluated by an outpatient provider within 30 days*
2. **Non-formulary long-acting opioids** may be approved when ALL the following criteria are met:
- a. Documentation has been submitted showing the following:
 - I. Patient has evidence of medical necessity supported by ONE of the following:
 - i. Therapeutic failure of two or more adequately dosed long-acting formulary opioids within the previous 180 days per pharmacy claims
 - ii. Allergy to one formulary drug
 - iii. Successful drug maintenance on the requested medication when changing to an alternative drug may produce a potential health risk
 - II. Prescriber has attested to ALL the following:
 - i. Prescriber has reviewed controlled substance prescriptions in the Prescription Drug Monitoring Program through CRISP (Chesapeake Regional Information System) for prescriptions from other providers
 - ii. Naloxone prescription has been provided or offered to patient/patient's household.
 - iii. Patient will have random urine drug screens
 - A. **Caveat: Urine drug screening is not applicable for patients being discharged from inpatient facility and transitioning to outpatient care*
 - iv. A Patient-Prescriber Pain Management/Opioid Treatment Agreement/Contract has been signed, and placed in the patient's medical record
 - A. **Caveats: Patient-Prescriber is not applicable for patients being discharged from inpatient facility and transitioning to outpatient care. However, provider must attest to ALL of the following:*
 1. *The risks and benefits associated with opioid use have been discussed with the patient/patient's household*
 2. *One of the following:*
 - a. *The prescribed treatment will be for less than 30 days*

 <p>JOHNS HOPKINS MEDICINE JOHNS HOPKINS HEALTHCARE</p>	Johns Hopkins HealthCare LLC Pharmacy Public Pharmacy Management Drug Policies	<i>Policy Number</i>	MEDS105	
		<i>Effective Date</i>	07/01/2017	
		<i>Review Date</i>	10/19/2022	
	<i>Subject</i>	PPMCO Short-Acting & Long-Acting Opioids	<i>Revision Date</i>	07/28/2022
			<i>Page</i>	3 of 5

b. *The need for further opioid use will be re-evaluated by an outpatient provider within 30 days*

B. Requests for **Formulary Short-acting Opioids at quantities that exceed 90 daily MME**, and **Formulary Long-acting Opioids** (*Formulary medications can be found here: https://www.ppmco.org/wp-content/uploads/2018/12/ppmco_formulary.pdf*):

1. Formulary products may be approved when the following criteria are met:

a. Documentation of ONE of the following:

- I. Patient has a diagnosis of cancer, sickle cell anemia, is in hospice care, in long-term care, or palliative care (diagnosis code Z51.5)
- II. Prescriber has attested to ALL the following:
 - i. Prescriber has reviewed controlled substance prescriptions in the Prescription Drug Monitoring Program through CRISP (Chesapeake Regional Information System) for prescriptions from other providers
 - ii. Naloxone prescription has been provided or offered to patient/patient's household.
 - iii. Patient will have random urine drug screens
 - A. **Caveat: Urine drug screening is not applicable for patients being discharged from inpatient facility and transitioning to outpatient care*
 - iv. A Patient-Prescriber Pain Management/Opioid Treatment Agreement/Contract has been signed, and placed in the patient's medical record
 - A. **Caveats: Patient-Prescriber is not applicable for patients being discharged from inpatient facility and transitioning to outpatient care. However, provider must attest to ALL of the following:*
 1. *The risks and benefits associated with opioid use have been discussed with the patient/patient's household*
 2. *One of the following:*
 - a. *The prescribed treatment will be for less than 30 days*
 - b. *The need for further opioid use will be re-evaluated by an outpatient provider within 30 days*


C. Requests for **Formulary Short-acting Opioids at quantities greater than Plan's Quantity Limits (QL)**

(*Quantity Limit of formulary medications can be found here: https://www.ppmco.org/wp-content/uploads/2018/12/ppmco_formulary.pdf):

1. Requests for quantities of short-acting opioids greater than the Plan's QLs may be approved when ALL the following criteria are met:

a. Documentation has been submitted showing the following:

- I. Documented diagnosis of severe chronic pain that requires a continuous, around-the-clock opioid analgesic for an extended period of time
- II. The patient has received a recent, documented pain management assessment by a physician
- III. The patient has tried and failed the recommended dosage interval of the requested medication
- IV. The requested dose does not exceed FDA recommendations or accepted clinical dosing guidelines
- V. The patient must be using an adequate dose of a long-acting (maintenance, around-the-clock) opioid
- VI. Other pain management regimens have been inadequate
- VII. Prescriber has attested to ALL the following:
 - i. A Patient-Prescriber Pain Management/Opioid Treatment Agreement/Contract has been signed, and placed in the patient's medical record

 <p>JOHNS HOPKINS MEDICINE JOHNS HOPKINS HEALTHCARE</p>	Johns Hopkins HealthCare LLC Pharmacy Public Pharmacy Management Drug Policies	<i>Policy Number</i>	MEDS105	
		<i>Effective Date</i>	07/01/2017	
		<i>Review Date</i>	10/19/2022	
	<i>Subject</i>	PPMCO Short-Acting & Long-Acting Opioids	<i>Revision Date</i>	07/28/2022
			<i>Page</i>	4 of 5

- ii. Naloxone prescription has been provided or offered to patient/patient's household
 - iii. Patient will have random urine drug screens
 - iv. Prescriber has reviewed controlled substance prescriptions in the Prescription Drug Monitoring Program through CRISP (Chesapeake Regional Information System) for prescriptions from other providers
- D. **Request for use of greater than a 7-day supply of formulary short-acting opioids** in an opioid-naïve patient (*Opioid naïve" is defined as patients who have not filled an opioid prescription within the previous 108 days*):
- 1. Requests for quantities of short-acting opioids greater than 7-day supply may be approved when the following criteria are met:
 - a. Documentation has been submitted showing that greater than a 7-day supply of the requested medication is medically necessary
 - b. The prescriber has reviewed controlled substance prescriptions in the Prescriptions Drug Monitoring Program through CRISP (Chesapeake Regional Information System) for prescriptions from other providers

III. OPIOID QUANTITY LIMITS

- A. QL is set at 90 MME per day for all opioids when total quantity is below 180 tablets/capsules/suppositories.
- B. QL is set at 180 tablets/capsules/suppositories for all other opioids
- C. QL for butorphanol 10mg/ml nasal spray is 10 ml
- D. QL for buprenorphine patches 5 per 30 days
- E. QL fentanyl patches 10 per 30 days
- F. QL for liquids is set at:
 - i. 1000 ml for all codeine containing oral solutions
 - ii. 2750 ml for all hydrocodone/acetaminophen oral solutions
 - iii. 675 ml for hydromorphone oral solution 1mg/ml
 - iv. 1800 ml for oxycodone oral solution 5mg/mL
 - v. 90mL for oxycodone concentrate solution 20mg/mL
 - vi. 1800 ml oxycodone acetaminophen oral solution 5-325mg/5ml
 - vii. 2700 ml meperidine oral solution 50mg/5ml

IV. AUTHORIZATION PERIOD/LIMITATIONS


- A. Initial approval for short-acting and long-acting opioids may be for up to 6 months.
- B. Approval for continuation of therapy may be extended in 12-month intervals with documentation showing beneficial patient response, as well as continued affirmation on the applicable attestations.

V. EXCLUSIONS

- A. Requests will not be approved for:
 - 1. Patients who do not meet above requirements
 - 2. Patient is currently taking or has a recent history of treatment for opiate dependence, including treatment with Suboxone, buprenorphine (Subutex), or methadone maintenance programs
- B. The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.

VI. REFERENCES

- 1. Johns Hopkins HealthCare Policy PHARM16: Requests for Non-formulary Medications.

 <p>JOHNS HOPKINS M E D I C I N E JOHNS HOPKINS HEALTHCARE</p>	Johns Hopkins HealthCare LLC Pharmacy Public Pharmacy Management Drug Policies	<i>Policy Number</i>	MEDS105	
		<i>Effective Date</i>	07/01/2017	
		<i>Review Date</i>	10/19/2022	
	<i>Subject</i>	PPMCO Short-Acting & Long-Acting Opioids	<i>Revision Date</i>	07/28/2022
			<i>Page</i>	5 of 5

2. Johns Hopkins HealthCare Policy PHARM20: Step Therapy, Prior Authorization and Quantity Limits
3. World Health Organization. Cancer pain relief. Geneva: World Health Organization, 1990.
4. Chou R et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. *J Pain* 2009; 10: 113-30
5. CDC guidance: <https://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm>
6. CMS guidance: <https://www.medicare.gov/federal-policy-guidance/downloads/cib-02-02-16.pdf>
7. DHMH website: <https://mmcp.dhmh.maryland.gov/healthchoice/opioid-dur-workgroup/Pages/medicaid-opioid-response.aspx>

VII. APPROVALS

Signature on file at JHHC

DATE OF REVISION	SUMMARY OF CHANGE
07/19/2017	MEDS 21 and MEDS 28 conversion to new policy MEDS 105 per DHMH regulations
07/27/2017	Updated Exclusions section regarding physician samples
04/16/2020	Criteria Layout Update (no criteria changes)
09/01/2020	Clarification of non-formulary opioid criteria
05/13/2021	Updated authorization guidance
07/28/2022	Criteria Layout Revision; Added criteria for 7-day supply exception

Review Date: 7/19/2017, 10/19/2022

Revision Date: 7/19/2017, 7/27/2017, 04/16/2020, 09/01/2020, 05/13/2021, 07/28/2022